Chaoju Ophthalmology (02219.HK) announced its interim results, with a net profit attributable to shareholders of 114 million yuan, a decrease of 16.72% year-on-year.

Zhtng Cijng APP News, Morningstar Ophthalmology (02219.HK) announced its interim performance for the six months ending on June 30, 2025. The group achieved a revenue of 698 million yuan, a decrease of 4.91% compared to the same period last year. The net profit attributable to the owners of the parent company was 114 million yuan, a decrease of 16.72% year-on-year. Earnings per share were 0.16 yuan.